Gemcitabine Plus S-1 as First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer: A Prospective Study

被引：0
|
作者：
Wu, W. [1 ]
Zheng, Y. [1 ]
Jiang, W. [1 ]
Liu, L. [1 ]
Tong, Z. [1 ]
Zhang, H. [1 ]
Fang, W. [1 ]
Zhao, P. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1548 / 1548
页数：1
相关论文
共 50 条
  • [31] A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Junji Furuse
    Taira Kinoshita
    Mitsuhiko Kawashima
    Hiroshi Ishii
    Masafumi Ikeda
    Shuichi Mitsunaga
    Satoshi Shimizu
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 527 - 534
  • [32] A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Nakachi, Kohei
    Furuse, Junji
    Kinoshita, Taira
    Kawashima, Mitsuhiko
    Ishii, Hiroshi
    Ikeda, Masafumi
    Mitsunaga, Shuichi
    Shimizu, Satoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 527 - 534
  • [33] Prognostic index based on the phase III study of gemcitabine plus S-1, S-1 alone or gemcitabine alone in patients with advanced pancreatic cancer (GEST study)
    Ueno, H.
    Nagase, M.
    Hamamoto, Y.
    Egawa, S.
    Ohkawa, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S462 - S462
  • [34] A phase II study of S-1 and irinotecan combination chemotherapy in patients with advanced gastric cancer as a first-line therapy
    Ryoo, B. Y.
    Kang, H. J.
    Yang, S. H.
    Cho, S. H.
    Oh, S. J.
    Lee, M. H.
    Song, E. K.
    Chung, H. C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 274 - 274
  • [35] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
    Kentaro Sudo
    Takeshi Ishihara
    Nobuto Hirata
    Fumiaki Ozawa
    Tadashi Ohshima
    Ryosaku Azemoto
    Kenji Shimura
    Takeshi Nihei
    Takayoshi Nishino
    Akihiko Nakagawa
    Kazuyoshi Nakamura
    Taro Hara
    Motohisa Tada
    Rintaro Mikata
    Katsunobu Tawada
    Osamu Yokosuka
    So Nakaji
    Taketo Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 389 - 396
  • [36] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
    Sudo, Kentaro
    Ishihara, Takeshi
    Hirata, Nobuto
    Ozawa, Fumiaki
    Ohshima, Tadashi
    Azemoto, Ryosaku
    Shimura, Kenji
    Nihei, Takeshi
    Nishino, Takayoshi
    Nakagawa, Akihiko
    Nakamura, Kazuyoshi
    Hara, Taro
    Tada, Motohisa
    Mikata, Rintaro
    Tawada, Katsunobu
    Yokosuka, Osamu
    Nakaji, So
    Yamaguchi, Taketo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 389 - 396
  • [37] A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer.
    Chiang, Nai-Jung
    Chen, Jen-Shi
    Chen, Ming-Huang
    Yang, Shih-Hung
    Hsu, Chiun
    Yen, Chia-Jui
    Tsou, Hsiao-Hui
    Shan Yanshen
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [38] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
    Cartwright, Thomas H.
    Arlen, Aimee Ginsburg
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] The efficacy of first-line chemotherapy in recurrent pancreatic cancer after S-1 adjuvant chemotherapy.
    Kanata, Ryo
    Ozaka, Masato
    Kataoka, Seita
    Ishigaki, Kazunaga
    Yamada, Ikuhiro
    Sasaki, Takashi
    Matsuyama, Masato
    Takano, Kouichi
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345